Objectives: This study aims to evaluate the efficacy and safety of integrative cancer treatment (collaborative Treatment with Korean and Western Medicine) in breast and gynecologic cancer patients. We analyzed the clinical outcomes of patients treated at the East-West Cancer Center to provide foundational data for further research on integrative oncology. Method: A retrospective chart review was conducted on 28 breast and gynecologic cancer patients who received both Western and Korean medicine treatments. Demographic data, survival rates, tumor response rates, and safety profiles were analyzed. Tumor response was assessed using response evaluation criteria in solid tumors criteria, and laboratory test, including interleukin-6 and tumor markers. Survival periods or progression-free survival of each patient were compared to the data from the literature. Safety was evaluated through laboratory tests, including liver and kidney function markers. Result: The tumor response rate in breast cancer patients was 100%, with a recurrence rate of only 6.25%. For ovarian cancer patients, two maintained complete remission, while one patient exceeded the median survival time by over 15 months. Also, endometrioid and cervical cancer patients showed extended survival. Tumor markers and interleukin-6 levels were used to evaluate treatment efficacy, with the majority of patients showing improvements. No grade 3 or higher adverse events were observed based on NCI-CTCAE standards, indicating that the integrative treatment was safe. Conclusion: The study suggests that integrative treatment for breast, ovarian, and uterine cancers may improve tumor response rates and prolong survival, with a low incidence of severe side effects. Future research with larger sample sizes and longer follow-up periods is necessary to further validate these findings and refine integrative oncology approaches.